홈 > 전체기사 > 기사
SK bioscience, Sanofi ink contract for five types of vaccines
기사입력 2024.03.27 08:25:02 | 최종수정 2024.03.27 08:37:33
[Photo provided by SK bioscience Co.]
The contract is valid until the end of 2024 and can be extended by mutual agreement. During this period, SK bioscience will be responsible for the overall distribution of Sanofi’s major vaccines in the country. The vaccines under the contract include three types of pediatric DTaP (diphtheria, tetanus, pertussis) combination vaccines (Tetraxim, Pentaxim, Hexaxim), an adult Tdap combination vaccine (Adacel Prefilled Syringe), and a meningococcal vaccine (Menactra). The market size in Korea for the five vaccines was approximately 25.9 billion won ($19.27 million) as of 2023.
“This partnership is yet another demonstration of our unique technological and production capabilities as well as our influence in the Korean market,” SK bioscience President Ahn Jae-yong said. “We will continue to expand our position as a leading vaccine company via global partnerships in various fields.”
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
관련기사
- 앨리스 소희, 사업가와 결혼 발표…연예계 은퇴
- 민희진 대표 “어도어 경영권 탈취 계획 없어”
- 조세호, 9세 연하 연인과 10월 20일 결혼
- 유이, 슬림 몸매로 장식한 독보적인 화보 공개
- 에이핑크 윤보미♥블랙아이드필승 라도 8년째 열애
|
MBN STAR 최신포토 | |||||||||||
|